Skip to main content

Table 6 Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on pulse wave velocity (PWV), augmentation index (AI), central diastolic and systolic blood pressure (CBDP and CSBP) in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

  Prior to L-NMMA infusion (at 70 min) During L-NMMA infusion (at 130 min)
PWV(m/s)
 Placebo 7.5 ± 1.1 8.0 ± 1.3*
 Tolvaptan 60 mg 7.6 ± 1.3 8.2 ± 1.4***
 p (paired t-test, between) 0.598 0.501
AI (n = 16)
 Placebo 21.1 ± 7.8 23.5 ± 7.3*
 Tolvaptan 60 mg 21.1 ± 8.9 21.9 ± 9.1
 p (paired t-test, between) 0.949 0.130
CSBP
 Placebo 132 ± 11 144 ± 18***
 Tolvaptan 60 mg 128 ± 9 139 ± 16***
 p (paired t-test, between) 0.084 0.124
CDBP (n = 17)
 Placebo 85 ± 9 93 ± 10***
 Tolvaptan 60 mg 83 ± 8 88 ± 9***
 p (paired t-test, between) 0.142 0.004
  1. Data are given as mean ± SD. Paired t-test (*) was performed for comparison of means during L-NMMA infusion vs prior to L-NMMA infusion. Paired t-test was also used for comparison between tolvaptan and placebo treatment prior to L-NMMA infusion (at 70 min) and during L-NMMA infusion (at 130 min)
  2. *p < 0.05; ***p < 0.0001